- Home
- SPHL vs BIVI Comparison
SPHL vs BIVI Comparison
Compare SPHL & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPHL
- BIVI
- Stock Information
- Founded
- SPHL 2002
- BIVI 2013
- Country
- SPHL Singapore
- BIVI United States
- Employees
- SPHL N/A
- BIVI N/A
- Industry
- SPHL Homebuilding
- BIVI Biotechnology: Pharmaceutical Preparations
- Sector
- SPHL Consumer Discretionary
- BIVI Health Care
- Exchange
- SPHL Nasdaq
- BIVI Nasdaq
- Market Cap
- SPHL 53.7M
- BIVI 45.1M
- IPO Year
- SPHL 2024
- BIVI N/A
- Fundamental
- Price
- SPHL $4.50
- BIVI $3.25
- Analyst Decision
- SPHL
- BIVI Strong Buy
- Analyst Count
- SPHL 0
- BIVI 2
- Target Price
- SPHL N/A
- BIVI $40.00
- AVG Volume (30 Days)
- SPHL 149.9K
- BIVI 16.9M
- Earning Date
- SPHL 11-25-2024
- BIVI 11-13-2024
- Dividend Yield
- SPHL N/A
- BIVI N/A
- EPS Growth
- SPHL 413.11
- BIVI N/A
- EPS
- SPHL 0.09
- BIVI N/A
- Revenue
- SPHL $11,020,429.00
- BIVI N/A
- Revenue This Year
- SPHL N/A
- BIVI N/A
- Revenue Next Year
- SPHL N/A
- BIVI N/A
- P/E Ratio
- SPHL $48.58
- BIVI N/A
- Revenue Growth
- SPHL 112.84
- BIVI N/A
- 52 Week Low
- SPHL $3.82
- BIVI $1.04
- 52 Week High
- SPHL $4.90
- BIVI $58.20
- Technical
- Relative Strength Index (RSI)
- SPHL N/A
- BIVI 62.20
- Support Level
- SPHL N/A
- BIVI $2.46
- Resistance Level
- SPHL N/A
- BIVI $3.61
- Average True Range (ATR)
- SPHL 0.00
- BIVI 0.34
- MACD
- SPHL 0.00
- BIVI 0.07
- Stochastic Oscillator
- SPHL 0.00
- BIVI 68.36
About SPHL Springview Holdings Ltd Class A Ordinary Shares
Springview Holdings Ltd is a company that conducts its operations through its indirect wholly-owned subsidiary which designs and constructs residential and commercial buildings in Singapore. It also provides four main types of works which includes new construction, reconstruction, Additions and Alterations (A&A), and other general contracting services such as renovation and design consultation.
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.